Skip to main content

Clinical Trials Using Zanzalintinib

Review the clinical trials studying zanzalintinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-17 of 17

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Status: Active
Location: 9 locations
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Status: Active
Location: 3 locations
XL092 with or without Nivolumab for the Treatment of Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Location: 2 locations
XL092 for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, PRO-XL Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
XL092 (Zanzalintinib) for the Treatment of Patients with Metastatic or Unresectable Leiomyosarcoma
Status: Active
Location: Northwestern University, Chicago, Illinois
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Zanzalintinib in Combination with Oral Etoposide for the Treatment of Relapsed and Refractory Metastatic Germ Cell Tumors
Status: Active
Location: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Zanzalintinib with Durvalumab plus Tremelimumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma, The ZENOBIA Trial
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Zanzalintinib Combined with Eribulin for the Treatment of Unresectable or Metastatic Liposarcoma and Leiomyosarcoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Zanzalintinib in Combination with Paclitaxel for the Treatment of Recurrent High Grade Uterine Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Zanzalintinib with Pembrolizumab and Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
XL092 and Cemiplimab for the Treatment of BRAF V600E-Wild Type Anaplastic Thyroid Cancer, NEO-COMBAT XL Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Zanzalintinib as Maintenance Therapy after Chemotherapy for the Treatment of High Grade Neuroendocrine Tumors
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Zanzalintinib for the Treatment of Locally Advanced Unresectable or Metastatic Bone Sarcomas, ZAMBONE Trial
Status: Approved
Location: M D Anderson Cancer Center, Houston, Texas
Zanzalintinib with Bone-Strengthening Agents for Treating Clear Cell Renal Cell Cancer Patients with Bone Metastases
Status: Approved
Location: University of California San Francisco, San Francisco, California
Zanzalintinib in Combination with Ipilimumab and Nivolumab for the Treatment of Metastatic or Unresectable Refractory Soft Tissue Sarcoma
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri